• 1
    Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994; 51: 563567.
  • 2
    Arthur RR, Hassan NF, Abdallah MY, el-Sharkawy MS, Saad MD, Hackbart BG, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg 1997; 91: 271274.
  • 3
    Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887891.
  • 4
    Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. HEPATOLOGY 2000; 32: 111115.
  • 5
    Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swifee Y, Abdel-Hamid M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg 2000; 63: 236241.
  • 6
    Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, et al. Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg 2001; 64: 147153.
  • 7
    Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. HEPATOLOGY 2001; 33: 248253.
  • 8
    Medhat A, Shehata M, Magder LS, Mikhail N, Abdel-Baki L, Nafeh M, et al. Hepatitis C in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002; 66: 633638.
  • 9
    Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 32743277.
  • 10
    Prati D, Capelli C, Silvani C, De Mattei C, Bosoni P, Pappalettera M, et al. The incidence and risk factors of community-acquired hepatitis C in a cohort of Italian blood donors. HEPATOLOGY 1997; 25: 702704.
  • 11
    Alter MJ. Epidemiology of hepatitis C. HEPATOLOGY 1997; 26(Suppl 1): 62S65S.
  • 12
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD. Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 2002; 40: 16561659.
  • 13
    Abdel-Hamid M, Edelman DC, Highsmith WE, Constantine NT. Optimization, assessment, and proposed use of a direct nested reverse transcription-polymerase chain reaction protocol for the detection of hepatitis C virus. J Hum Virol 1997; 1: 5865.
  • 14
    Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications, 1982: 529.
  • 15
    Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. HEPATOLOGY 2000; 31: 13341337.
  • 16
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. HEPATOLOGY 2000; 32: 9196.
  • 17
    Vogt M, Lay T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866870.
  • 18
    Al-Shirbiny M, Osman A, Mohamed N, Shata MT, Abdel-Aziz, F, Abdel-Hamid M, et al. Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg 2005; in press.
  • 19
    Sasaki F, Tanaka J, Moriya T, Katayama K, Hiraoka M, Ohishi K, et al. Very low incidence rates of community-acquired hepatitis C virus infection in company employees, long-term inpatients, and blood donors in Japan. J Epidemiol 1996; 6: 198203.
  • 20
    Okayama A, Stuver SO, Tabor E, Tachibana N, Kohara M, Mueller NE, et al. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepatol 2002; 9: 4351[Japan]. Transfusion 1997;37:564-565.
  • 21
    Fukuizumi K, Sata M, Suzuki H, Nakano H, Tanikawa K. Hepatitis C virus seroconversion rate in a hyperendemic area of HCV in Japan: a prospective study. Scand J Infect Dis 1997; 29: 345347.
  • 22
    Lu SN, Chue PY, Chen IL, Wang JH, Huang JF, Peng CF, et al. Incidence of hepatitis C infection in a hepatitis C endemic township in southern Taiwan. Kaohsiung J Med Sci 1997; 13: 605608.
  • 23
    Sun CA, Chen HC, Lu SN, Chen CJ, Lu CF, You SL, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001; 65: 3034.
  • 24
    Rao MR, Naficy AB, Darwish MA, Darwish NM, Schisterman E, Clemens JD, et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis 2002; 2: 29.